Regulatory press release

Lipum AB – interim report Q2 for the period January-June 2025

Lipum AB (publ) has published the interim report Q2 for the period January-June 2025. Below is a summary, a complete report (only in Swedish) is available on the company's website.

Financial summary January – June 2025

Other operating income: 760 KSEK (94)
Result after financial items: -36 618 KSEK (-28 109)
Cash and cash equivalents as of June 30: 1 674 KSEK (20 131)

Significant events during the period

Lipum announces the successful completion and publication of the Clinical Study Report (CSR) for SOL-116 – the findings support further clinical development

Significant events after the period

Lipum announces outcome of warrant program for employees, key consultants, and board members – 89% subscribed.
Lipum appoints Tobias Helgesson as new Chief Financial Officer (CFO).
Lipum secures bridge loan to cover the company’s operating expenses during 2025

CEO Ola Sandborgh comments – “Time for Planning and Preparation!”

2025 will be a year in which we conclude a significant project while at the same time taking the next big step forward. I am of course referring to our Phase 1 study, where in April we were able to communicate and share the positive results we achieved. The study confirmed that our drug candidate SOL-116 is safe and well tolerated, with low immunogenicity and predictable pharmacokinetics. In addition, the exploratory analyses showed reduced levels of the target protein BSSL, indicating a direct target effect, a highly important validation ahead of the next phase.

Key milestones have been reached, our drug development is progressing, and we are gradually strengthening our scientific position. Our research continues to deliver clear results and is well worth supporting. With confidence and determination, we can now move forward according to plan and take SOL-116 into Phase 2, where we intend to study treatment effects in patients with moderate to severe rheumatoid arthritis (RA). This represents a very exciting and, at the same time, value-creating step in our development.

Ola Sandborgh, CEO

Ola Sandborgh comments on the report in a live webcast on August 28 at 10:00 (in Swedish only) LINK .

The complete report (only in Swedish) is available at www.lipum.se

About Us
Lipum AB (publ) is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in clinical phase with a successfully completed Phase 1 study. Together with strong preclinical data, we have a solid foundation for continued development in the treatment of rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.